MOCHIDA PHARMACEUTICAL CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,290 JPY | 0.00% |
|
+5.62% | +0.61% |
| Apr. 25 | Hidehiro Imatsu named president of Goldman Sachs Japan | RE |
| Mar. 21 | Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023. | CI |
Valuation
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 161,603 | 164,177 | 141,444 | 116,879 | 114,243 | 116,635 | - | - |
| Enterprise Value (EV) 1 | 100,313 | 100,691 | 79,530 | 56,370 | 67,454 | 52,493 | 50,058 | 46,925 |
| P/E ratio | 35.5 x | 19.3 x | 13.5 x | 18.7 x | 25.4 x | 19.8 x | 17.6 x | 15.8 x |
| Yield | 1.92% | 2.1% | 2.41% | 2.4% | 2.48% | 2.43% | 2.43% | 2.43% |
| Capitalization / Revenue | 1.59 x | 1.59 x | 1.28 x | 1.13 x | 1.11 x | 1.1 x | 1.08 x | 1.06 x |
| EV / Revenue | 0.99 x | 0.98 x | 0.72 x | 0.55 x | 0.66 x | 0.5 x | 0.46 x | 0.43 x |
| EV / EBITDA | 8.69 x | 6.83 x | 4.66 x | 5.04 x | 7.83 x | 5.2 x | 4.55 x | 3.91 x |
| EV / FCF | - | - | - | 11 x | - | 14.3 x | 10.2 x | 8.37 x |
| FCF Yield | - | - | - | 9.1% | - | 6.98% | 9.82% | 11.9% |
| Price to Book | 1.34 x | 1.29 x | 1.09 x | 0.96 x | 0.89 x | 0.89 x | 0.86 x | 0.84 x |
| Nbr of stocks (in thousands) | 38,754 | 38,270 | 37,870 | 34,994 | 35,479 | 35,452 | - | - |
| Reference price 2 | 4,170 | 4,290 | 3,735 | 3,340 | 3,220 | 3,290 | 3,290 | 3,290 |
| Announcement Date | 5/15/20 | 5/14/21 | 5/13/22 | 5/15/23 | 5/13/24 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 101,799 | 102,995 | 110,179 | 103,261 | 102,885 | 106,000 | 108,000 | 110,000 |
| EBITDA 1 | 11,538 | 14,745 | 17,081 | 11,179 | 8,610 | 10,100 | 11,000 | 12,000 |
| EBIT 1 | 8,807 | 12,003 | 14,392 | 8,507 | 5,802 | 7,500 | 8,500 | 9,500 |
| Operating Margin | 8.65% | 11.65% | 13.06% | 8.24% | 5.64% | 7.08% | 7.87% | 8.64% |
| Earnings before Tax (EBT) 1 | 6,273 | 11,900 | 14,591 | 9,044 | 6,160 | 7,600 | 8,600 | 9,600 |
| Net income 1 | 4,598 | 8,587 | 10,569 | 6,649 | 4,547 | 5,900 | 6,650 | 7,400 |
| Net margin | 4.52% | 8.34% | 9.59% | 6.44% | 4.42% | 5.57% | 6.16% | 6.73% |
| EPS 2 | 117.6 | 222.3 | 277.4 | 178.9 | 126.8 | 166.1 | 187.2 | 208.3 |
| Free Cash Flow 1 | - | - | - | 5,131 | - | 3,666 | 4,917 | 5,605 |
| FCF margin | - | - | - | 4.97% | - | 3.46% | 4.55% | 5.1% |
| FCF Conversion (EBITDA) | - | - | - | 45.9% | - | 36.3% | 44.7% | 46.71% |
| FCF Conversion (Net income) | - | - | - | 77.17% | - | 62.14% | 73.94% | 75.74% |
| Dividend per Share 2 | 80.00 | 90.00 | 90.00 | 80.00 | 80.00 | 80.00 | 80.00 | 80.00 |
| Announcement Date | 5/15/20 | 5/14/21 | 5/13/22 | 5/15/23 | 5/13/24 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2021 S1 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 51,623 | 54,009 | 30,805 | 25,365 | 27,692 | 25,508 | 53,200 | 28,194 | 21,867 | 24,747 | 24,729 | 49,476 | 28,742 | 24,667 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 7,229 | 6,131 | 6,914 | 1,347 | 4,265 | 1,014 | 5,279 | 5,077 | -1,849 | 2,515 | 1,437 | 3,952 | 1,839 | 11 |
| Operating Margin | 14% | 11.35% | 22.44% | 5.31% | 15.4% | 3.98% | 9.92% | 18.01% | -8.46% | 10.16% | 5.81% | 7.99% | 6.4% | 0.04% |
| Earnings before Tax (EBT) | 7,353 | 6,793 | 6,964 | - | 4,414 | - | 5,412 | 5,195 | - | 2,572 | - | 4,049 | 1,994 | - |
| Net income 1 | 5,411 | 4,916 | 5,264 | 389 | 3,155 | 768 | 3,923 | 4,158 | -1,432 | 1,688 | 1,150 | 2,838 | 1,606 | 103 |
| Net margin | 10.48% | 9.1% | 17.09% | 1.53% | 11.39% | 3.01% | 7.37% | 14.75% | -6.55% | 6.82% | 4.65% | 5.74% | 5.59% | 0.42% |
| EPS | 139.6 | 128.5 | 137.8 | - | 83.98 | - | 104.6 | 111.8 | - | 46.24 | - | 78.39 | 45.09 | - |
| Dividend per Share | 40.00 | 40.00 | - | - | - | - | 40.00 | - | - | - | - | 40.00 | - | - |
| Announcement Date | 11/2/20 | 11/5/21 | 2/4/22 | 5/13/22 | 8/1/22 | 11/4/22 | 11/4/22 | 2/6/23 | 5/15/23 | 8/4/23 | 11/2/23 | 11/2/23 | 2/5/24 | 5/13/24 |
1JPY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 61,290 | 63,486 | 61,914 | 60,509 | 46,789 | 64,142 | 66,577 | 69,710 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | 5,131 | - | 3,666 | 4,917 | 5,605 |
| ROE (net income / shareholders' equity) | 3.7% | 6.9% | 8.3% | 5.2% | 3.6% | 4.5% | 5% | 5.4% |
| ROA (Net income/ Total Assets) | 5.78% | 7.68% | 9.11% | 5.64% | 3.8% | 4.7% | 5.2% | 5.7% |
| Assets 1 | 79,490 | 111,813 | 116,028 | 117,819 | 119,618 | 125,532 | 127,885 | 129,825 |
| Book Value Per Share 2 | 3,114 | 3,318 | 3,424 | 3,470 | 3,610 | 3,698 | 3,806 | 3,934 |
| Cash Flow per Share | 187.0 | 293.0 | 348.0 | 251.0 | 205.0 | - | - | - |
| Capex 1 | 1,958 | 1,935 | 2,988 | 2,166 | 2,296 | 2,000 | 2,500 | 2,500 |
| Capex / Sales | 1.92% | 1.88% | 2.71% | 2.1% | 2.23% | 1.89% | 2.31% | 2.27% |
| Announcement Date | 5/15/20 | 5/14/21 | 5/13/22 | 5/15/23 | 5/13/24 | - | - | - |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.61% | 726M | |
| +56.89% | 823B | |
| -6.55% | 353B | |
| +15.99% | 320B | |
| +7.92% | 295B | |
| +14.12% | 239B | |
| +14.92% | 220B | |
| -0.20% | 219B | |
| +7.94% | 167B | |
| -2.57% | 159B |
- Stock Market
- Equities
- 4534 Stock
- Financials Mochida Pharmaceutical Co., Ltd.
